These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7922383)

  • 1. Anti-endotoxin antibodies and other inhibitors of endotoxin.
    Zanetti G; Glauser MP; Baumgartner JD
    New Horiz; 1993 Feb; 1(1):110-9. PubMed ID: 7922383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of endotoxemia and septicemia.
    Baumgartner JD; Glauser MP
    Immunobiology; 1993 Apr; 187(3-5):464-77. PubMed ID: 8330909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.
    Cross AS; Opal S; Cook P; Drabick J; Bhattacharjee A
    Vaccine; 2004 Feb; 22(7):812-7. PubMed ID: 15040932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiendotoxin therapies for septic shock.
    Corriveau CC; Danner RL
    Infect Agents Dis; 1993 Feb; 2(1):44-52. PubMed ID: 8162353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an anti-endotoxin vaccine for sepsis.
    Cross AS
    Subcell Biochem; 2010; 53():285-302. PubMed ID: 20593272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
    Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS
    J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting endotoxin in the treatment of sepsis.
    Rachoin JS; Schorr CA; Dellinger RP
    Subcell Biochem; 2010; 53():323-38. PubMed ID: 20593274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of endotoxin neutralization by synthetic cationic compounds.
    Andrä J; Gutsmann T; Garidel P; Brandenburg K
    J Endotoxin Res; 2006; 12(5):261-77. PubMed ID: 17059690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of serological specificity of anti-endotoxin sera directed against whole bacterial cells and core oligosaccharide of Escherichia coli J5-tetanus toxoid conjugate.
    Lukasiewicz J; Jachymek W; Niedziela T; Malik-Gebicka M; Dzieciatkowska M; Lugowski C
    Acta Biochim Pol; 2002; 49(3):721-34. PubMed ID: 12422242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis.
    Dunn DL; Priest BP; Condie RM
    Arch Surg; 1988 Nov; 123(11):1389-93. PubMed ID: 3178488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endotoxin binding to erythrocyte membrane and erythrocyte deformability in human sepsis and in vitro.
    Pöschl JM; Leray C; Ruef P; Cazenave JP; Linderkamp O
    Crit Care Med; 2003 Mar; 31(3):924-8. PubMed ID: 12627006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis.
    Opal SM
    Int J Med Microbiol; 2007 Sep; 297(5):365-77. PubMed ID: 17452016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic perspectives of severe infectious states].
    Offenstadt G; Guidet B; Barakett V
    Rev Prat; 1993 Jan; 43(1):59-64. PubMed ID: 8469900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules.
    David SA
    J Mol Recognit; 2001; 14(6):370-87. PubMed ID: 11757070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.